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spinal cord injury alters a number of endogenous biological signals known to be in-
volved in the modulation of neurotrophic and neuroprotective events. nerve growth 
factor (ngF) is a neurotrophic factor expressed in neuronal and non-neuronal tissues 
including spinal cord, and increases after spinal cord injury. Recent findings revealed 
that leptin, an adipocyte-derived cytokine (adipokine), enhance neuronal survival and 
exert neuroprotective action, and played an important role in nociceptive behavior 
induced by nerve injury. Whether ngF affects the expression of leptin in injured spi-
nal cord has not been investigated. The present study was designed to evaluate: (i) 
whether intranasal ngF administration reached the spinal cord of the rat, (ii) if ngF 
affects the expression of leptin in the spinal cord and adipose tissue, and (iii) whether 
intranasal ngF affects the behavioral and spinal cord neuronal deficits induced by spi-
nal cord injury. The result showed that intranasal ngF enhances the expression of (i) 
ngF and ngF-receptors (Trka and p75nTR) in injured spinal cord exerting behavioral 
and neuroprotective action, and (ii) leptin in injured spinal cord and in subcutaneous 
(white) and interscapular (brown) adipose tissue. altogether, the present data demon-
strate the efficacy of intranasal administration of ngF, and suggest a link between the 
neurotrophin ngF and the adipokine leptin that may be therapeutically explored in 
injured spinal cord. 
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introduction
The nerve growth factor (NGF) and 
its receptors, TrkA and p75NTR, are 
known to play a critical role in the sur-
vival, and protective action in a num-
ber of nerve cells of the peripheral and 
central nervous systems (1-3). NGF 
and receptors are also expressed in the 
spinal cord (4,5), but the functional 
significance of these NGF signals in 
spinal cord injury (SCI) is not clear. 
Spinal cord injury has been shown to 
alter, not only NGF expression, but 
also other endogenous biological sig-
nals, including leptin, an adipocyte-
secreted cytokine (adipokine) (6-9), 
which has been shown to enhance 
neuronal survival in vitro and in vivo 
and reduce experimentally induced 
neuronal damages (10-12). It has also 
been reported that SCI can be associ-
ated with obesity and altered circu-
lating levels of various adipokine in-
cluding leptin (6,7,13,14), while NGF 
administration can restore synaptic 
inputs in axotomized spinal cord mo-
toneurons (15-17). However, whether 
a correlation exists between NGF sig-
nals and leptin in SCI has not been 
investigated. 
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Other findings have shown that large molecules, including 
NGF can be delivered to the central nervous system (18-20), in-
cluding spinal cord (21), via olfactory pathways reaching brain 
neurons through the anatomical connections, naso-lacrimal 
duct and brain ventricles. These observations suggested investi-
gating the effect of intranasal (IN) NGF administration on spi-
nal cord injury, leptin levels in the spinal cord and adipose tissue 
in adult rats with SCI. The results showed that this non-invasive 
method of NGF administration can reach the spinal cord, reduce 
the deficit of locomotor activity, induced by SCI, and enhances 
the presence of leptin, in both spinal cord and adipose tissue. 
materials and methods 
2-month old male Sprague-Dawley rats raised in our animal 
facilities were used for this study. The animals were housed in 
polypropylene cages (2 animal per cage) under standard light/
dark conditions with food pellets and water at libitum. 
Surgery. Animals (n=22) were deeply anesthetized with in-
traperitoneal injection of 3% pentobarbital sodium (30mg/kg). 
The spinal cord was exposed at the level of the vertebral seg-
ments T8-T10. The T10 vertebral lamina and the dura matter 
were removed, and a surgical lesion was done to the half por-
tion of the spinal cord. Before closing the wounded tissues, the 
animal received one intrathecal administration of 5ug of NGF 
dissolved in 5ul of physiological solution. The first intrathecal 
injection of 5ul of NGF was followed by 10ul of daily intranasal 
(IN) NGF administration of (200ug/ml, dissolved in physiologi-
cal solution), for 3 consecutive weeks. An equal number of rats 
received IN administration of physiological solution and served 
as controls (CTRL). 
Post-operative period included feeding care twice a day, con-
stant room temperature, manual abdominal compression un-
til urinal reflex was established and urinary bladder evacuated 
for operation. The mortality rate during and immediately after 
surgery was less than 10%. All experimental procedures were 
approved by the local animal committee and carried out in ac-
cordance with the Guidelines for the care and use of Laboratory 
Animals published by National Institutes of Health, USA.
NGF administration
The NGF used for this experiment was purified from adult male 
mouse submaxillary salivary gland following the method de-
scribed by Bocchini and Angeletti (22). Once purified, aliquots 
of NGF were dissolved in physiological solution (0.9% NaCl) at 
concentration 200 µg/ml and stored at –70°C until used for topi-
cal nasal administration. 
Locomotor behavior. To test the locomotor activity and the 
effect of NGF, we measured the time that each animals need to 
reach a food source distant one meter. The effect of NGF admin-
istration was evaluated using a semiquantatative analysis for the 
hind limb function as described (23). 
Biochemical analyses. Animals were sacrificed with an over-
dose of 3% pentobarbital sodium (30mg/Kg) and injured and 
non-injured spinal cord, as well as subcutaneous adipose tissue 
and brown adipose tissue (from interscapular area), carefully re-
moved and immediately stored at -80°C for NGF, NGF receptor 
and leptin determinations. 
NGF determination. Tissues were homogenized with ultra-
sonication in Radio Immune Precipitation Assay (RIPA) buffer 
(10 mM tris-HCl, pH7.4; 100 mM NaCl; 1 mM EDTA; 1 mM 
EGTA; 1% Triton X-100; 10% glycerol; 0.1% SDS; 2 mM Na-
3VO4; 20 mM Na4P2O7; 1 mM NaF; 2 mg/ml aprotinin; 1mM 
PMSF; 1µg/ml leupeptin), centrifuged at 4°C for 20 min at 
13000 rpm, then supernatant was recovered and used for NGF, 
determination as suggested by the instructions provided by the 
manufacturers. (NGF ELISA kits, Emax Immuno Assay System, 
were purchased from Promega (Madison, WI, USA). Assays 
were performed in duplicate and the data are expressed as con-
centration of growth factors pg/µg of total proteins. 
Western blot analysis of leptin. Briefly, tissues were homog-
enized with ultrasonication in RIPA buffer (50 mM tris-HCl, 
pH7.4; 150 mM NaCl; 5 mM EDTA;; 1% Triton X-100; 0.1% 
SDS; 0,5% DOC (Sodium deoxycholate; 1mM PMSF; 1µg/ml 
leupeptin), centrifuged at 4° C for 20 min at 13000 rpm, then su-
pernatant was storage at -20°C. Samples (30μg of total protein) 
were dissolved in loading buffer (0.1 M Tris–HCl buffer, pH 6.8, 
containing 0.2 M dithiothreitol, DTT, 4% sodium-dodecil-phos-
phate, SDS, 20% glycerol, and 0.1% bromophenol blue), separat-
ed by 8% or 12% SDS-PAGE, and electrophoretically transferred 
to PVDF membrane overnight. The membranes were incubated 
for 1 hr at room temperature with blocking buffer constituted by 
5% BSA (for TrkA) or non-fat dry milk (for GAPDH) in TBS-
T (10 mM Tris, pH 7.5, 100 mM NaCl, and 0.1% Tween-20). 
Membranes were washed three times for 10 minutes each at 
room temperature in TBS-T followed by incubation at 4°C 
with primary antibodies overnight polyclonal rabbit anti-TrkA 
1:1000 (Santa Cruz biotechnology, CA, USA), polyclonal rabbit 
anti-leptin 1:1000 (Santa Cruz biotechnology, CA, USA). Mem-
branes were washed three times for 10 minutes each at room 
temperature in TBS-T and incubated for 1 hour with horserad-
ish peroxidase-conjugated anti-rabbit IgG 1:4000 or horseradish 
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peroxidase-conjugated anti-mouse IgG as the secondary anti-
body (Cell Signaling Technology, MA, USA) at room tempera-
ture. The blots were developed with an ECL chemiluminescent 
horseradish peroxidase (HRP) substrate as the chromophore 
(Millipore, MA, USA). The public Image J Software was used 
to evaluate band density, which was expressed as arbitrary units 
of grey level. The Image J program determines the optical den-
sity of the bands using a grey scale shareholding operation. The 
optical density of polyclonal rabbit anti-GAPDH 1:4000 (Santa 
Cruz biotechnology, CA, USA) bands was used as a normalizing 
factor. For each gel blot, the normalized values were then ex-
pressed as percentage of relative normalized controls and used 
for statistical evaluation. 
Histological and immunohistochemical analyses. The 
animals were deeply anesthetized and perfused through the as-
cending aorta, first with physiological solution and then phos-
phate buffer 0.1M, pH 7.4 followed by 300 ml of buffered 4/% 
paraformaldhehyde. The spinal cord was removed, post-fixed 
overnight with the same fixative and then in phosphate buffer 
containing 20% of sucrose. Coded twenty-micron thick sections 
were then cut with a cryostat and stained with toluidine blue 
for histological observation or immunostained for localization 
of NGF receptor and leptin.
For immunohistochemical staining, spinal cord sections sec-
tioned with a cryostat, at 20 micron thick, followed by expo-
sure to 0.1M PBS containing 10% of horse or goat serum for 1 
hour, then incubated overnight at 4°C with monoclonal mouse 
anti-p75 1:100, rabbit anti-leptin (Santa Cruz, CA, USA). After 
washing, sections, after having been washed, were then exposed 
to biotinylated anti-mouse or anti-rabbit IgG 1:300 (anti-IgG 
and avidin-conjugated horseradish peroxidase complex) were 
purchased by Vector Laboratories (Burlingame, CA, USA) with 
2% of goat or horse serum, depending on the animal in which 
the secondary antibody was produced, for 2 hours at room 
temperature, and then to immunoperoxidase staining was per-
formed using an ABC (1:100) (Avidin-Biotin complex solution, 
Vectastain Elite Kit (Vector Laboratories, CA, USA) for 2 hours 
at room temperature. All the sections studied passed through 
all procedures simultaneously to minimize any difference from 
immunohistochemical staining itself. Signals were visualized 
by DAB (3,3’-diaminobenzidine) as a chromate. Sections incu-
bated identically with normal IgG was used as negative controls. 
Stained sections were visualized using a Zeiss Axiophot micro-
scope equipped with a 40X objective with the aid of a computer-
ized image analysis system. Sections (n=10) of each NGF-treat-
ed and NGF-untreated rats were used for a quantitative analysis 
to count the number of immunostained spinal cord cells in 8 
fields of 4 section of 4 different rat per experimental group as 
previously described (24). 
Statistical Analysis 
Statistical evaluations were performed using the Stat View pack-
age for Windows and data were expressed as mean±SEM. A 
post-hoc comparison within logical sets of means was performed 
using Tukey’s test. A p-value of less than 0.05 was considered 
significant. ELISA and western blot (n=6 for each experimental 
group) were evaluated by one-way ANOVA.Post-hoc compari-
sons were performed using the Tukey’s HSD test. A p-value less 
than 0.05 were considered significant.
results
Figure 1A shows an anesthetized rat after spinal cord injury that 
was induced in the gray matter. The lesion of the spinal cord 
causes neuronal damages and inflammatory cell infiltration, in-
cluding mast cells increase (Fig.1C). Figure 1D reports the lo-
comotor activity of CTRL rats, rat with SCI, and rats with SCI 
treated for 3 weeks with IN NGF administration (SCI/NGF). 
The non-operated rats need 8 sec to reach the food source, rats 
with SCI treated with NGF 12 sec, whereas rats with SCI but 
untreated with NGF needs more that 30 sec. 
Intranasal NGF reaches the injured spinal cord
The levels of NGF in the injured spinal cord increases after IN 
NGF administration (SCI plus NGF) compared to controls and 
operated untreated rats (Fig. 2A). NGF administration can by-
pass the blood-brain barrier and can reach injured spinal cord 
neurons. Quantitative evaluation indicates that the increase is 
statistically significant (Fig. 2D).
Structural analyses
Since the low-affinity NGF p75NTR is implicated in mediating 
survival of injured motoneurons after axotomy (22), we studied 
the expression of this receptor. Immunohistochemical analysis 
performed on section of spinal cord of the three rat groups re-
vealed that p75NTR neurons are more numerous in the injured 
spinal cord of rats treated with NGF (SCI plus NGF), compared 
to the injured spinal cord of NGF untreated rats (SCI). In spi-
nal cord sections immunostained with p75NTR, the number of 
p75NTR-positive neurons are markedly reduced as compared to 
controls, while IN NGF administration reduced the SCI, though 
not completely (Fig. 3). Nonetheless, quantitative evaluation in-
dicated that the differences are statistical significant. This obser-
vation suggests that large molecular size, like NGF, can reach 
spinal cord neurons via olfactory pathways (21) and can exert 
neuroprotective action. 
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Figure 1. Illustration of anesthetized rat with lesion in the dorsal region (arrow) after spinal cord surgical injury in the dorsal 
horn (a). a representative section of the spinal cord showing nerve cells in the gray matter (gm) and glial cells in the white mat-
ter (Wm.); the lesion was induced in the gm region (B). This lesion causes neuronal damages infl ammatory cell infi ltration (c), 
including increase of mast cells. The results of locomotor activity of cTRl, rat with scI, and rats with scI treated for 3 weeks with 
ngF administration (scI/ngF), evaluated as the time needed to cover a distance of 1 meter (D). note that the non-operated rats 
need 8 sec to reach the food source, rats with scI treated with ngF 12 sec and rats with scI but untreated with ngF over 30 sec. 
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Figure 2. levels of ngF in the spinal cord of rats untreated and treated with In ngF (a). The concentration of ngF in injured 
spinal cord treated for 3 consecutive weeks with In ngF administration (scI/ngF) increase, compared to control (ctRl) and op-
erated ngF untreated rats (scI), p<0.05 compared and untreated injured spinal cord (scI). Expression of Trka protein evaluated 
with western blot in the spinal cord of in injured spinal cord treated for 3 consecutive weeks with In ngF administration (scI/






















































Figure 3. Representative spinal cord section of control (a), injured untreated (B) and injured ngF-treated (c) rats, 3 weeks 
after daily nasal ngF administration, and immunostained with the low-affi  nity ngF receptor, p75nTR. note the loss of this ngF-
receptor in neurons of the gray matter after scI, (B), compared to control spinal cord neurons, and the protective action after 
ngF administration, indicated by arrows. Quantitative evaluation indicated that these diff erences are statistically signifi cant (D). 
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Western blot analysis. NGF administration enhanced the 
expression of the high-affinity NGF TrkA receptor compared to 
control rats and untreated SCI (Fig. 3B). 
Spinal cord injury had no effect on NGF levels in blood and 
adipose tissues, while NGF administration enhances the con-
centration of NGF in spinal cord and adipose tissue (Fig. 4). 
Intranasal NGF administration alters leptin levels in spinal cord 
Because a number of studies indicate that SCI is associated with 
obesity, we evaluated the presence of leptin in the spinal cord and 
in subcutaneous adipose tissue. Immunohistochemical and West-
ern blot analysis indicated that the levels of leptin is enhanced by 
SCI, and NGF administration reduced this increase, though the 
level of leptin remains above the control levels (Fig. 5).
Discussion
Leptin is an adipokine exerting its actions via endocrine and 
paracrine pathway, playing a well-known key regulatory action 
on food intake and energy expenditure, also inflammation and 
immunity (6,7). Recent studies have demonstrated that leptin, 
like NGF, can affect neuronal survival in vitro and in vivo and 
reduce experimentally induced neuronal damages (10,12) and 
that NGF is expressed and released by adipose tissues (25,26). 
However, whether there is any functional relationship between 
these two endogenous signals in SCI has not been investigated. 
The present study was designed to evaluate: (i) whether IN 
NGF administration reached the spinal cord, (ii) if NGF affects 
the expression of leptin in the spinal cord and adipose tissue, 
and (iii) whether NGF affected the behavioral and spinal cord 
injury induced by SCI. 
Figure 4. shows the levels of ngF in the serum (a), subcu-
taneous adipose tissue (B) and brown adipose tissue (c) in 
control rats and injured spinal cord untreated (sc) and treat-
ed while In ngF administration enhances the levels of ngF 
in both subcutaneous adipose tissue (B) and brown adipose 
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Figure 5. leptin immunoassayed representative sections of rat’s spinal cord of cTRl (a), injured ngF untreated (B) and injured 
ngF-treated injured spinal cord for three weeks (c). note the absence of leptin immonostaining in control spinal cord (a), the 
marked increase after scI (B) compared to control and ngF-treated (D). magnifi cation, a-c: X 170. Western blot analysis of con-





















Regarding the fi rst question we found that IN NGF admin-
istration reaches the injured spinal cord neurons and enhances 
the expression of TrkA NGF receptor and p75NTR. Since these 
receptors regulate the biological activity of the NGF (2,27), this 
observation suggests that the nasal NGF administration reaches 
the spinal cord as functional active molecule. Th e fact that three 
consecutive weeks of NGF administration protects the degen-
erating neurons in injured spinal cord supports this hypothesis. 
Because leptin promotes neuronal activity (10-12), and has 
been indicated as a possible mediator of therapeutic target for 
degenerating brain neurons (26-30), we tested whether NGF ad-
ministration aff ects the expression of leptin. It was found that IN 
NGF administration enhances the level of leptin in the injured 
spinal cord compared to controls, suggesting a possible bidirec-
tional functional activity between NGF and leptin.
A critical question raised by these observations regards the 
source of NGF and the role of NGF on leptin level. Since a num-
ber of non-adipose cells produces leptin (4,6,26,29) and a num-
ber of non-neuronal cells produces NGF (31-35), the possibility 
that diff erent cell types produce and release both NGF and leptin 
and thus in tandem exert a protective action on spinal cord cells 
cannot be excluded. Indeed, data reporting that combination of 
diff erent molecules can enhance neuroprotection and functional 
recovery following SCI support this hypothesis. 
In summary, the present pilot study provided the fi rst con-
vinced evidence that injured spinal cord neurons respond to 
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nasal NGF by enhancing the expression of both NGF/receptors 
and leptin and that administration of NGF via olfactory path-
ways, most likely similar to ocular administration (38). Whether 
prolonged nasal NGF administration, alone or in combination 
with leptin, reduces and/or delay neurodegeneration in the spi-
nal cord and whether the effect is long lasting need to be inves-
tigated. Since NGF has been used for certain human disorders, 
it might be of interest further experimental studies to investigate 
the potential benefits of IN NGF in injured spinal cord neurons 
and in the absence of invasive and undesired side effects, not 
only in animal models. 
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